SCHEMBL6476402

SCHEMBL6476402

CC(C)(C)c1ccc(-c2noc(COc3cccc4cc(NS(=O)(=O)C(F)(F)F)ccc34)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.50
EGFR P00533 1/20 0.45
EPHA2 P29317 1/20 0.45
KDR P35968 1/20 0.45
EPHB4 P54760 1/20 0.45
MAPT P10636 12/20 0.45
SMN1; SMN2 Q16637 8/20 0.44
MAPK1 P28482 4/20 0.41
TSHR P16473 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TP53 P04637 5/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477166 0.91 MAPK1 (0.52) PPARAMAPTSMN1; SMN2MAPK1TSHR
SCHEMBL6484697 0.91 PPARA (0.49) PPARAMAPTSMN1; SMN2MAPK1TSHR
SCHEMBL6477186 0.90 PPARA (0.47) PPARAEPHA2KDREPHB4MAPT
SCHEMBL6486872 0.88 PPARA (0.46) PPARAMAPTMAPK1TSHRTDP1
SCHEMBL6486994 0.87 FFAR1 (0.49) PPARAMAPTSMN1; SMN2L3MBTL1TP53
SCHEMBL6484693 0.83 CYSLTR2 (0.43) MAPTEPHX2ALDH1A1
SCHEMBL6476335 0.82 EPHX2 (0.42) EPHX2
SCHEMBL6477856 0.81 CYSLTR2 (0.42) PPARAEPHX2
SCHEMBL6486939 0.81 CNR2 (0.40) PPARATSHRALDH1A1LMNA
SCHEMBL6475810 0.80 CYSLTR2 (0.42) PPARAEGFREPHA2KDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933322-B2 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2005-08-23 US disclosed
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus INSR, GPR119, SLC5A1 PPARA 491/4885EGFR 1941/4885EPHA2 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.